actually you don't have to wait 30 days. That's a very misunderstood rule. Traders buy and sell the same stock everyday, many times a days.
Always. Crazy things happen.
wow, all the way to $15. Disappointing to say the least. That's not exactly a ringing endorsement to buy the stock.
the close could be interesting today
For those that are wondering WHY the AXON drug will pass this time it's because the FDA has "dramatically" lowered the Alzheimer's bar for approval. This is because there are no drugs that are really effective so they are willing to make it easier to get approval . AXON's drug is super low risk because it is used in combination with other drugs, meaning they only need to demonstrate modest improvement and the FDA will give the green light. THINK!!!
FDA proposes to dramatically lower the bar on Alzheimer's drugs
Just weeks after pointing R&D groups engaged in Alzheimer's drug research to early-stage patients, the FDA is proposing to lower the bar biotechs will have to clear in order to gain an approval. And faced with a string of blockbuster collapses in Phase III, regulators are signaling a greater willingness to offer early, accelerated approvals for the most promising therapies that come out of the pipeline.
July 15, 2015: In a report published Wednesday, JMP Securities analyst Jason N. Butler initiated coverage of Axovant Sciences Ltd with a Market Outperform rating and a price target of $36.
Axovant is a biopharmaceutical company focused on the development and commercialization of novel treatments for dementia, including Alzheimer's disease (AD). The company is conducting a confirmatory Phase 3 trial for RVT-101, its lead candidate, as an adjunct therapy to donepezil in patients with mild-to moderate AD.
"We believe the probability of success for this Phase 3 trial is high, based on a clear mechanistic rationale for synergistic benefits with donepezil, and positive results from a large randomized, controlled, Phase 2b trial in the same patient population," analyst Jason N. Butler wrote.
In the report JMP Securities noted, "RVT-101 is being developed as an add-on therapy to donepezil and there is both mechanistic and clinical evidence to support clinically important benefits of combining these drug modalities. We also see commercial advantages to an add-on therapy, with targeted patients already receiving treatment for their disease, which we believe will speed RVT-101's adoption."
Jefferies initiates coverage on Axovant Sciences (NYSE: AXON) with a Buy rating and a price target of $31.00.
July 6, 2015
Analyst Biren Amin commented, "We believe AXON's lead product candidate RVT-101 is well-characterized for the treatment of Alzheimer's disease and with proper development effort could be approved as an add-on to donepezil (Aricept) and having already shown cognitive and functional benefit in the disease. While AD alone could generate $2.6B in risk-adjusted sales in 2025, we believe additional RVT-101 indications and further pipeline acquisitions could provide significant upside for AXON."
There is no way the CEO would be making a special presentation to investors AFTER he presents to the Alzheimer's conference on Wednesday if he didn't have GREAT news. Here is what their PR states:
July 1, 2015 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will host an investor briefing on July 22 at 5:45 p.m. EDT FOLLOWING its presentation of RVT-101 clinical data at the Alzheimer's Association International Conference 2015 (AAIC).
The event will include the following remarks:
•Dr. Lawrence Friedhoff, Chief Development Officer, will present an overview of Axovant's lead drug candidate RVT-101, including data presented earlier that day at AAIC
•Dr. Atul Pande, Axovant Director, who previously led the development of RVT-101 as SVP, Neurosciences at GlaxoSmithKline, will offer commentary on the RVT-101 clinical data
•Dr. Gary Small, President of the American Association of Geriatric Psychiatry (AAGP), will offer additional commentary
we will see $26+ next week.